arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Larimar Therapeutics, Inc.

LRMR
$4.16 ▼ -0.03 (-0.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Larimar Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC -15.6%
FCF / Share None
Trailing P/E
Price / Book 2.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-29.61M
↓ -1.1%
FCF / Share Free cash flow per share
$-0.30
↓ -38.2%
Long-Term Debt Long-term obligations
$16.36M
↓ -10.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters